EZH2 mutations frequently occur in myeloproliferative/myeloproliferative neoplasms, myelodysplastic syndromes, and myelofibrosis, while CML cases are mainly characterized by EZH2 overexpression [18]. Here, EZH2 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.